In contrast, CD25+ Tregs, CD66b+ neutrophils, CD68+CD163+ M2 macrophages, and S100A4+CD163+ cells were not related to clinical outcomes in patients with glioma. This evidence concerns the gene CD163 and central nervous system cancer.